Mektovi (binimetinib) — CareFirst (Caremark)
Cutaneous melanoma
Preferred products
- dabrafenib (Tafinlar)
- trametinib (Mekinist)
Initial criteria
- Unresectable or metastatic disease with a BRAF V600 activating mutation (e.g., V600E or V600K) when used in combination with encorafenib (Braftovi)
- Neoadjuvant treatment of BRAF V600 mutation-positive cutaneous melanoma in combination with encorafenib (Braftovi) if immunotherapy is contraindicated when the member has had an unacceptable toxicity to dabrafenib (Tafinlar) in combination with trametinib (Mekinist) or dabrafenib/trametinib are less desirable based on side-effect profiles
- Adjuvant treatment of resected stage III disease with a BRAF V600 activating mutation (e.g., V600E or V600K) in combination with encorafenib (Braftovi) when the member has had an unacceptable toxicity to dabrafenib (Tafinlar) in combination with trametinib (Mekinist) or dabrafenib/trametinib are less desirable based on side-effect profiles
- Limited resectable local satellite/in-transit recurrent disease with a BRAF V600 activating mutation (e.g., V600E or V600K) in combination with encorafenib (Braftovi) when the member has had an unacceptable toxicity to dabrafenib (Tafinlar) in combination with trametinib (Mekinist) or dabrafenib/trametinib are less desirable based on side-effect profiles
- Locally advanced unresectable or metastatic NRAS-mutant melanoma, as a single agent, when the member is previously untreated or has experienced disease progression on or after prior immunotherapy
Reauthorization criteria
- Continued treatment when there is no evidence of unacceptable toxicity or disease progression while on the current regimen
Approval duration
12 months